CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients

Stock Information for CorMedix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CorMedix Inc.

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
CorMedix Inc. to Present at the Needham Annual Healthcare Conference
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
CorMedix Inc. Announces Commercial and Reimbursement Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.